AGP Limited
By PSX Investors Zone · Updated October 20, 2026
AGP Limited (AGP) is a Pakistan Stock Exchange-listed pharmaceutical company involved in importing, marketing, exporting, distributing, wholesaling and manufacturing pharmaceutical products. In 2025, it reported standalone sales of approximately Rs. 20.55 billion, profit after tax of Rs. 2.36 billion and EPS of Rs. 8.43. Its portfolio and subsidiaries support its presence across Pakistan’s healthcare market. Investors should examine earnings growth, product demand, regulatory requirements, distribution costs, debt and the latest Shariah screening before making investment decisions.
Company Overview
AGP Limited is a Pakistani pharmaceutical company incorporated in May 2014 and listed on the Pakistan Stock Exchange on March 5, 2018. Its principal activities include importing, marketing, exporting, dealership, distribution, wholesale and manufacturing of pharmaceutical products.
According to the PSX profile, Aitkenstuart Pakistan (Private) Limited holds 55.80% of AGP's share capital, while West End 16 Pte Limited, Singapore, is the ultimate parent company.
Official references: PSX AGP profile | AGP official website
Business Model
AGP operates in the pharmaceutical and healthcare sector. Its business includes pharmaceutical product marketing, distribution and manufacturing. Its performance can be influenced by product demand, pricing and regulatory decisions, raw-material and import costs, foreign-exchange movements, competition, distribution expenses and product portfolio development.
AGP's annual report also discusses the performance of its subsidiaries, including OBS AGP and OBS PK. When reviewing results, distinguish the standalone financial statements of AGP Limited from the consolidated results of the group.
Source: AGP Annual Report 2025.
Annual Financial Performance
The following figures are the standalone annual financial figures shown on the PSX profile. Amounts are in Pakistani rupees.
| Financial metric | FY2025 | FY2024 |
|---|---|---|
| Sales | Rs. 20.546 billion | Rs. 18.544 billion |
| Profit after tax | Rs. 2.360 billion | Rs. 2.084 billion |
| Earnings per share (EPS) | Rs. 8.43 | Rs. 7.44 |
| Gross profit margin | 48.62% | 47.84% |
| Net profit margin | 11.49% | 11.24% |
In FY2025, sales increased by approximately 10.8% and profit after tax increased by approximately 13.3% compared with FY2024. Gross and net profit margins also improved slightly. These results indicate stronger reported annual performance, but they do not establish that the same growth rate will continue.
Source: Official PSX financial profile. PSX notes that its standardised financial data may differ from the issuer's original reports; consult the audited annual report for detailed analysis.
Latest Half-Year Results
PSX lists financial results for the six months ended June 30, 2026. Its displayed quarterly data includes the following standalone figures:
| Metric | Q1 2026 | Q2 2026 |
|---|---|---|
| Sales | Rs. 5.387 billion | Rs. 3.747 billion |
| Profit after tax | Rs. 556.92 million | Rs. 318.91 million |
| EPS | Rs. 1.99 | Rs. 1.14 |
The two quarters together represent sales of approximately Rs. 9.134 billion and profit after tax of approximately Rs. 875.84 million. These figures should be checked against the original half-year report before publication, especially if comparing them with consolidated results or earlier periods.
Sources: PSX AGP financials and announcements | AGP official website.
Share Price and Valuation
The PSX profile showed the following market data on October 20, 2026, at approximately 3:46 PM:
| Market metric | Displayed value |
|---|---|
| Share price | Rs. 160.18 |
| Trailing P/E ratio | 20.91 |
| 52-week price range | Rs. 146.11–258.67 |
| One-year price change | -17.76% |
| Year-to-date price change | -21.15% |
These figures are time-sensitive and should be refreshed from PSX before publishing.
The P/E ratio compares a share's market price with its earnings per share. It should be assessed alongside earnings growth, cash flows, debt, valuation history and pharmaceutical-sector conditions. A price decline alone does not establish that a share is undervalued.
Source: Official PSX AGP quote.
Dividend Information
For the year ended December 31, 2025, AGP's Board recommended a final cash dividend of Rs. 8 per share, subject to shareholder approval. PSX also lists a notice dated September 10, 2026, confirming credit of interim cash dividends.
Before displaying the final FY2025 dividend as approved or paid, check the relevant AGM and payout records. For the interim dividend, confirm the applicable period and entitlement details from the official announcement.
Sources: AGP Annual Report 2025 | PSX AGP announcements and payouts.
Shariah Compliance Status
AGP was listed as Shariah-compliant in the screening review effective June 5, 2026, based on accounts to December 31, 2025.
| Screening measure | Reported ratio |
|---|---|
| Debt ratio | 7.27% |
| Non-compliant investments ratio | 0.05% |
| Non-compliant income ratio | 0.19% |
| Illiquid assets ratio | 85.99% |
Source: AGP screening record and official notice reference.
Important: This status applies to the stated review and reporting period. Shariah screening can change at subsequent reviews. Verify AGP against the latest official PSX/KMI Shariah-compliant securities notice before relying on the status for investment decisions.
Key Business Risks
- Regulatory risk: Pharmaceutical products are subject to regulatory approvals, quality requirements and government policies.
- Pricing pressure: Changes in product pricing and competition can affect sales and margins.
- Import and foreign-exchange exposure: Imported inputs and currency movements may influence costs.
- Product concentration: Dependence on particular brands or therapeutic categories can affect results.
- Distribution and operating costs: Marketing, logistics and administrative costs can influence profitability.
- Subsidiary and integration risk: Group results may depend on subsidiary performance and the management of acquired businesses.
- Market and valuation risk: Share prices can move independently of short-term business performance.
- PSX Risk Warning Alert: The PSX company profile displays an alert concerning continuous violation of clauses 5.11.1 or 5.11.2 and possible suspension or delisting risk. Check the latest official PSX notice to understand the current status. This alert does not by itself prove that trading has already been suspended or that AGP has been delisted.
Source: Official PSX AGP profile.
Investor Research Checklist
Before researching AGP, review:
- The latest annual report and half-year financial statements.
- Sales and profit trends across comparable reporting periods.
- Standalone versus consolidated results.
- Cash flows, borrowings, finance costs and working-capital requirements.
- Product portfolio, pricing, regulation and competition.
- Official dividend announcements and payout history.
- The latest PSX risk notices and Shariah screening status.
Official References
- Pakistan Stock Exchange — AGP profile, market quote, financials and announcements
- AGP Limited official website
- AGP Annual Report 2025
- AGP Shariah screening details
Disclaimer
This profile is for educational and informational purposes only. It is not a recommendation to buy or sell AGP shares and does not guarantee returns. Financial figures, prices, dividends, risk alerts and Shariah status may change. Review the latest official company disclosures and PSX records before making investment decisions.
This profile is for educational purposes and is not a recommendation to buy or sell any security.